Fresenius Tempers Expectations For Adalimumab Biosimilar

 
• By Aidan Fry
  
Hand
Investors should not expect a major contribution to turnover this year from Fresenius Kabi's Idacio adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products